Encapsulation of alendronate sodium by nanoprecipitation and double emulsion: From preparation to in vitro studies

Industrial Crops and Products

Volumn 72, Issue , 2015, Pages 24-33

  Miladi, K ^a,b,c   Sfar, S ^c   Fessi, H ^a   Elaissari, A ^a  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Alendronate sodium; Double emulsion evaporation; In vitro; Nanoparticles; Nanoprecipitation; Osteoporosis; Polycaprolactone

Indexed keywords

BIOCHEMISTRY; BIOCOMPATIBILITY; DISEASES; DRUG PRODUCTS; EMULSIFICATION; ENCAPSULATION; EVAPORATION; MOLECULAR WEIGHT; MOLECULES; PARTICLE SIZE; POLYCAPROLACTONE; POLYMERS; SODIUM;

ALENDRONATE SODIUMS (ALN); DOUBLE EMULSIONS; IN-VITRO; NANO PRECIPITATIONS; OSTEOPOROSIS;

NANOPARTICLES;

DISEASE TREATMENT; DRUG; EMULSION; ENCAPSULATION; MOLECULAR ANALYSIS; NANOTECHNOLOGY; PARTICLE SIZE; PHOSPHATE; POLYMER; PRECIPITATION (CHEMISTRY); STABILIZATION;

EID: 84937978478     PISSN: 09266690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.indcrop.2015.01.079     Document Type: Article

References (41)

1. Bilati U., Allémann E., Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci. 2005, 24:67-75. 10.1016/j.ejps.2004.09.011.
2. Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int. J. Pharm. 2007, 336:367-375. 10.1016/j.ijpharm.2006.11.061.
3. Campos E.V.R., de Melo N.F.S., de Paula E., et al. Screening of conditions for the preparation of poly(-caprolactone) nanocapsules containing the local anesthetic articaine. J. Colloid Sci. Biotechnol. 2013, 2:106-111. 10.1166/jcsb.2013.1040.
4. Cauchetier E., Deniau M., Fessi H., et al. Atovaquone-loaded nanocapsules: influence of the nature of the polymer on their in vitro characteristics. Int. J. Pharm. 2003, 250:273-281.
5. Chorny M., Fishbein I., Danenberg H.D., Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size drug recovery and release kinetics. J. Controlled Release 2002, 83:389-400. 10.1016/S0168-3659(02)211-0.
6. Cohen-Sela E., Chorny M., Koroukhov N., et al. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J. Controlled Release 2009, 133:90-95. 10.1016/j.jconrel.2008.09.073.
7. Cohen-Sela E., Rosenzweig O., Gao J., et al. Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J. Controlled Release 2006, 113:23-30. 10.1016/j.jconrel.2006.03.010.
8. Contado C., Vighi E., Dalpiaz A., Leo E. Influence of secondary preparative parameters and aging effects on PLGA particle size distribution: a sedimentation field flow fractionation investigation. Anal. Bioanal. Chem. 2013, 405:703-711. 10.1007/s00216-012-6113-5.
9. Cremers S.C., Pillai G., Papapoulos S.E. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin. Pharmacokinet. 2005, 44:551-570.
10. Dash T.K., Konkimalla V.B. Poly-j{cyrillic, ukrainian}-caprolactone based formulations for drug delivery and tissue engineering: a review. J. Controlled Release 2012, 158:15-33. 10.1016/j.jconrel.2011.09.064.
11. De Araújo T.M., Teixeira Z., Barbosa-Sampaio H.C., et al. Insulin-loaded poly(epsilon-caprolactone) nanoparticles: efficient sustained and safe insulin delivery system. J. Biomed. Nanotechnol. 2013, 9:1098-1106.
12. De Melo N.F.S., Campos E.V.R., de Paula E., et al. Factorial design and characterization studies for articaine hydrochloride loaded alginate/chitosan nanoparticles. J. Colloid Sci. Biotechnol. 2013, 2:146-152. 10.1166/jcsb.2013.1048.
13. Dhanaraju M.D., Jayakumar R., Vamsadhara C. Influence of manufacturing parameters on development of contraceptive steroid loaded injectable microspheres. Chem. Pharm. Bull. 2004, 52:976-979.
14. M.S. El-Aasser, J. Ugelstad, J.W. Vanderhoff, (1979). Polymer emulsification process.
15. Ezra A., Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv. Drug Delivery Rev. 2000, 42:175-195.
16. Fasinu P., Pillay V., Ndesendo V.M.K., et al. Diverse approaches for the enhancement of oral drug bioavailability. Biopharm. Drug Dispos. 2011, 32:185-209. 10.1002/bdd.750.
17. Fessi H., Puisieux F., Devissaguet J.P., et al. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 1989, 55:R1-R4. 10.1016/0378-5173(89)90,281-0.
18. Florence A.T., Whitehill D. The formulation and stability of multiple emulsions. Int. J. Pharm. 1982, 11:277-308. 10.1016/0378-5173(82)90,080-1.
19. Fonseca C., Simões S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Controlled Release 2002, 83:273-286.
20. Grando C.R.C., Guimarães C.A., Mercuri L.P., et al. Preparation and characterization of solid lipid nanoparticles loaded with racemic mitotane. J. Colloid Sci. Biotechnol. 2013, 2:140-145. 10.1166/jcsb.2013.1044.
21. Han S., Li M., Liu X., et al. Construction of amphiphilic copolymer nanoparticles based on gelatin as drug carriers for doxorubicin delivery. Colloids Surf. B Biointerfaces 2013, 102:833-841. 10.1016/j.colsurfb.2012.09.010.
22. Lankveld J.M., Lyklema J. Adsorption of polyvinyl alcohol on the paraffin-water interface. II. Spread and adsorbed monolayers. J. Colloid Interface Sci. 1972, 41:466-474. 10.1016/0021-9797(72)90,370-0.
23. Lindfors L., Skantze P., Skantze U., et al. Amorphous drug nanosuspensions. 1. Inhibition of ostwald ripening. Langmuir 2006, 22:906-910. 10.1021/la0523661.
24. Lira A.A.M., Cordo P.L.A., Nogueira E.C.F., et al. Optimization of topical all-trans retinoic acid penetration using poly-DL-lactide and poly-DL-lactide-co-glycolide microparticles. J. Colloid Sci. Biotechnol. 2013, 2:123-129. 10.1166/jcsb.2013.1041.
25. Martín-Banderas L., Alvarez-Fuentes J., Durán-Lobato M., Prados J., Melguizo C., Fernández-Arévalo M., Holgado M.A., et al. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. Int. J. Nanomed. 2012, 7:5793-5806. 10.2147/IJN.S34633.
26. Mazzaferro S., Bouchemal K., Maksimenko A., et al. Reduced intestinal toxicity of docetaxel loaded into mucoadhesive nanoparticles in mouse xenograft model. J. Colloid Sci. Biotechnol. 2012, 1:210-217. 10.1166/jcsb.2012.1022.
27. Mishra P.R., Al Shaal L., Müller R.H., Keck C.M. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int. J. Pharm. 2009, 371:182-189. 10.1016/j.ijpharm.2008.12.030.
28. Mittal G., Sahana D.K., Bhardwaj V., Ravi Kumar M.N.V. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Controlled Release 2007, 119:77-85. 10.1016/j.jconrel.2007.01.016.
29. Ostović D., Stelmach C., Hulshizer B. Formation of a chromophoric complex between alendronate and copper(II) ions. Pharm. Res. 1993, 10:470-472. 10.1023/A.1018969112754.
30. Perez C., Sanchez A., Putnam D., et al. Poly (lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Controlled Release 2001, 75:211-224. 10.1016/S0168-3659(01)397-2.
31. Puga A.M., Rey-Rico A., Magariños B., et al. Hot melt poly-ε-caprolactone/poloxamine implantable matrices for sustained delivery of ciprofloxacin. Acta Biomater. 2012, 8:1507-1518. 10.1016/j.actbio.2011.12.020.
32. Riddick TM, inc Z-M (1968) Control of colloid stability through zeta potential: with a closing chapter on its relationship to cardiovascular disease. Published for Zeta-Meter, inc., by Livingston Pub. Co.
33. Rosset V., Ahmed N., Zaanoun I., et al. Elaboration of argan oil nanocapsules containing naproxen for cosmetic and transdermal local application. J. Colloid Sci. Biotechnol. 2012, 1:218-224. 10.1166/jcsb.2012.1023.
34. Sanna V., Roggio A.M., Posadino A.M., et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co- glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies. Nanoscale Res. Lett. 2011, 6:260. 10.1186/1556-276X-6-260.
35. ® RS 100 blend submicron particles for the sustained release of the antiretroviral efavirenz. Colloids Surf. B Biointerfaces 2013, 102:441-449. 10.1016/j.colsurfb.2012.06.038.
36. Sinha V.R., Bansal K., Kaushik R., et al. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int. J. Pharm. 2004, 278:1-23. 10.1016/j.ijpharm.2004.01.044.
37. Sweetman SC. (2009) Martindale: The Complete Drug Reference. Pharmaceutical Press.
38. Van de Ven H., Vermeersch M., Matheeussen A., et al. PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: factor influence study and in vitro efficacy evaluation. Int. J. Pharm. 2011, 420:122-132. 10.1016/j.ijpharm.2011.08.016.
39. Wang F., Li J., Wang C. Hydrophilic and fluorescent colloidal nanorods of MWNTs as effective targeted drug carrier. J. Colloid Sci. Biotechnol. 2012, 1:192-200. 10.1166/jcsb.2012.1024.
40. Yadav K.S., Sawant K.K. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr. Drug Deliv. 2010, 7:51-64.
41. Zili Z., Sfar S., Fessi H. Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin. Int. J. Pharm. 2005, 294:261-267. 10.1016/j.ijpharm.2005.01.020.